Waldencast PLC

Waldencast PLC(WALD)の株式分析

$1.350

-0.039 (-2.88%)終値時点

Loading chart…
High
1.370
Open
1.370
VWAP
1.34
Vol
227.45K
Mkt Cap
478.98M
Low
1.315
Amount
305.92K
EV/EBITDA, TTM
21.56

Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States.

AI analysis of Waldencast PLC (WALD)

hold

Waldencast PLC is currently not a strong buy due to its recent financial performance and analyst downgrades, despite some positive catalysts. The stock is trading at $1.34, with a forward P/E of 45.045, suggesting high expectations for future earnings. However, the company reported a Q4 net loss of $33.5 million and has seen a significant decline in its stock price, down 21.64% year-to-date. The main risk is the ongoing strategic review and disappointing sales performance, particularly in the Milk Makeup brand, which could hinder recovery.

バリュエーション指標

The current forward P/E ratio for Waldencast PLC (WALD) is 45.05, compared to its 5-year average forward P/E of 20.28.

Forward P/E

Fair
5Y Average P/E
20.28
Current P/E
45.05
割高
141.69
割安
-101.14

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
13.72
Current EV/EBITDA
21.56
割高
20.14
割安
7.30

Forward P/S

Undervalued
5Y Average P/S
1.82
Current P/S
0.54
割高
2.91
割安
0.73

Alphio AI Price Scenarios for WALD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%WALD

$3.01

シナリオ価格

B

Base

Base · 50%WALD

$2.59

シナリオ価格

B

Bear

Bear · 25%WALD

$2.24

シナリオ価格

イベントタイムライン

2026-06-15 (ET)

09:30:00

Waldencast Receives FDA Approval for Obagi saypha ChIQ Injectable Hyaluronic Acid Gel

2026-06-02 (ET)

06:50:00

Canaccord Raises Waldencast Price Target to $3

2026-06-01 (ET)

07:40:00

Waldencast Sells Obagi Medical Skincare Business for Up to $460M

2026-03-19 (ET)

08:40:00

Obagi Medical Collaborates with ProMD Health on Hyaluronic Acid Program

2026-03-13 (ET)

07:00:00

Waldencast Reports Q4 Adjusted EBITDA of $6.6M

ニュース

WALD FAQ — answered by Alphio AI

Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States. It operates in the Consumer Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Waldencast PLC is currently not a strong buy due to its recent financial performance and analyst downgrades, despite some positive catalysts. The stock is trading at $1.34, with a forward P/E of 45.045, suggesting high expectations for future earnings. However, the company reported a Q4 net loss of $33.5 million and has seen a significant decline in its stock price, down 21.64% year-to-date. The main risk is the ongoing strategic review and disappointing sales performance, particularly in the Milk Makeup brand, which could hinder recovery.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める